Eli Lilly and Company (LLY) 79.67 $LLY
Testosterone Replacement Therapy (TRT) Market to Face Lean Patch until 2024 as it Inches Close to Patent Cliff, Says TMR
PR Newswire Europe - Tue Jul 12, 11:31AM CDT
ALBANY, New York, July 12, 2016 /PRNewswire/ --
AGN: 239.70 (+1.42), ENDP: 17.39 (+0.23), LLY: 79.67 (+0.53), ABBV: 65.50 (+1.15)
2016 INVESTIndiana Equity Conference Announces Corporate Presentation Lineup
BusinessWire - Tue Jul 12, 10:00AM CDT
INVESTIndiana, an equity conference that highlights the performance of Indiana public companies, today announced a presentation lineup that features Indiana's top health sciences companies as well as leaders in the banking, energy, high-tech and manufacturing sectors.
ESCA: 10.06 (+0.24), ININ: 43.64 (+0.92), ZBH: 125.46 (+0.38), GABC: 34.02 (+0.96), KBAL: 11.72 (+0.01), HBNC: 26.34 (+0.27), LLY: 79.67 (+0.53), LKFN: 48.01 (+0.96), SRCE: 33.11 (+0.40), ONB: 12.94 (+0.28), ECYT: 3.24 (+0.05), NI: 25.86 (-0.21), INBK: 24.63 (+0.25), BASI: 1.20 (-0.03), MFSF: 28.64 (+0.28)
Technical Report on Drug Manufacturers - Major Stocks - Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and GlaxoSmithKline
PR Newswire - Mon Jul 11, 6:55AM CDT
On Friday, July 08, 2016, the NASDAQ Composite ended the trading session at 4,956.76, up 1.64%; the Dow Jones Industrial Average advanced 1.40%, to finish at 18,146.74; and the S&P 500 closed at 2,129.90, up 1.53%. The gains were broad based as all the sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Bristol-Myers Squibb Company (NYSE: BMY), AstraZeneca PLC (NYSE: AZN), Eli Lilly and Company (NYSE: LLY), and GlaxoSmithKline PLC (NYSE: GSK). Learn more about these stocks by accessing their free notes at:
AZN: 30.20 (+0.23), LLY: 79.67 (+0.53), GSK: 43.72 (+0.20), BMY: 76.20 (+0.81)
Lilly Diabetes Welcomes Acclaimed Singer/Songwriter Crystal Bowersox as Newest Spokesperson
PR Newswire - Wed Jul 06, 5:45AM CDT
Crystal Bowersox understands how crucial it is to properly manage diabetes and find a healthy balance on and off the stage. Diagnosed with type 1 diabetes at age 6, Crystal - now 30 - rose from humble beginnings in northwestern Ohio to reach the heights of American Idol in 2010 and an ongoing musical career that has followed. Having nearly lost her spot on the show due to a short hospitalization brought on by the rigorous taping and rehearsal schedule, she vowed to make it her mission to touch others impacted by diabetes with her music and her message.
LLY: 79.67 (+0.53)
Top 6 Research Reports for July 1, 2016
Sheraz Mian - Zacks Investment Research - Fri Jul 01, 12:59PM CDT
Top 6 Research Reports for July 1, 2016
FDX: 159.95 (+2.84), HII: 173.14 (-0.72), CCL: 46.71 (+1.08), LLY: 79.67 (+0.53), ORCL: 41.42 (+0.64), WEN: 9.78 (unch)
Merus Labs Appoints Two New Senior Executives
PR Newswire - Thu Jun 30, 3:00PM CDT
Merus Labs International Inc. ("Merus" or the "Company"
(TSX: MSL, NASDAQ: MSLI) is pleased to announce two key additions to its executive leadership team effective July 1, 2016.
LLY: 79.67 (+0.53), MSLI: 1.28 (+0.03)
Eli Lilly Stock Up on FDA Advisory Panel Vote for Jardiance
Arpita Dutt - Zacks Investment Research - Thu Jun 30, 8:50AM CDT
Lilly (LLY) and its partner, Boehringer, are seeking FDA approval for the inclusion of data from the EMPA-REG OUTCOME study, which showed cardiovascular risk reduction.
JNJ: 122.92 (-0.01), NVO: 55.55 (+0.19), MRK: 59.60 (+0.26), LLY: 79.67 (+0.53)
SmarTrend Watching for Potential Pullback in Shares of Eli Lilly After 3.89% Gain
Comtex SmarTrend(R) - Wed Jun 29, 12:45PM CDT
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $75.87 to a high of $78.14. Yesterday, the shares gained 3.9%, which took the trading range above the 3-day high of $76.25 on volume of 3.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
LLY: 79.67 (+0.53)
Lilly Confirms Date And Conference Call For Second-Quarter 2016 Financial Results Announcement
PR Newswire - Tue Jun 28, 12:37PM CDT
Eli Lilly and Company (NYSE: LLY) will announce its financial results for the second quarter of 2016 on Tuesday, July 26, 2016. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance.
LLY: 79.67 (+0.53)
Lilly Convenes Leaders at National Mayor's Conference to Address Impact of Alzheimer's Disease on Local Communities
PR Newswire - Mon Jun 27, 1:30PM CDT
With the prevalence of Alzheimer's disease expected to triple by 2050, there is an urgent need for greater awareness of the economic and social impact of the disease on families, communities and health systems. In an effort to educate and activate local communities to plan for this emerging public health crisis, Eli Lilly and Company (NYSE:LLY) today kicked off an expansion of its Community Conversations on Alzheimer's series with a panel discussion at the U.S. Conference of Mayors meeting in Indianapolis, Indiana.
LLY: 79.67 (+0.53)
Elanco Animal Health Announces One Health Antibiotic Stewardship Summit
PR Newswire - Mon Jun 27, 10:40AM CDT
Last June leaders from across human and animal health gathered at the White House Forum on Antibiotic Stewardship to improve antibiotic stewardship and to protect long-term effectiveness of antibiotics. Building on the collaboration created at that event, Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY), is announcing a One Health Antibiotic Stewardship Summit for global industry and food chain leaders to continue building dialogue and actions that address this challenge.
LLY: 79.67 (+0.53)
Incyte Gains on Jakafi's Breakthrough Status for Acute GVHD
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 5:07PM CDT
Incyte (INCY) announced that the FDA has granted Breakthrough Therapy status to Jakafi for the treatment of patients with acute graft-versus-host disease.
INCY: 84.97 (-0.03), LLY: 79.67 (+0.53), BMY: 76.20 (+0.81), NVS: 81.68 (-0.63)
Diabetes Scholars Foundation Announces 2016 Scholarship Recipients
PR Newswire - Thu Jun 23, 9:00AM CDT
If the caliber of students receiving a Lilly Diabetes Tomorrow's Leaders Scholarship is any indication, the future is in good hands. The 2016 scholarship winners, announced today online at www.diabetesscholars.org by the Diabetes Scholars Foundation (Foundation), refused to let type 1 diabetes stand in the way of academic and community service excellence.
LLY: 79.67 (+0.53)
MacroStat Receives 2016 Lilly Global Supplier Award
BusinessWire - Wed Jun 22, 10:51AM CDT
MacroStat, a leading biometrics CRO fully owned by Tigermed (ChiNext SZ: 300347), has received the 2016 Lilly Global Supplier Award that recognizes MacroStat's outstanding performance in the area of biometrics services for Eli Lilly and Company (NYSE: LLY).
LLY: 79.67 (+0.53)
Cancer Drug News Issue - Global Expansion of Portrazza will Aid in Supporting Eli Lilly's Lung Cancer Franchise - Research and Markets
BusinessWire - Tue Jun 21, 12:32PM CDT
Research and Markets has announced the addition of the "Cancer Drug News Issue 670" report to their offering.
LLY: 79.67 (+0.53)
Lilly Declares Third-Quarter 2016 Dividend
PR Newswire - Mon Jun 20, 12:00PM CDT
The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2016 of $0.51 per share on outstanding common stock.
LLY: 79.67 (+0.53)
Elanco, EnBiotix Establish Collaboration Exploring Engineered Phage Technology
BusinessWire - Thu Jun 16, 7:00AM CDT
Today Elanco Animal Health, a division of Eli Lilly and Company, (NYSE: LLY) and EnBiotix, Inc., announced a collaboration to explore the application of EnBiotix's engineered phage technology in specific animal health targets. If successful, this endeavor could result in potential alternatives for traditional antibiotics in animals.
LLY: 79.67 (+0.53)
German Supreme Court Grants Lilly Appeal in Alimta® Vitamin Regimen Patent Lawsuit
PR Newswire - Tue Jun 14, 5:15PM CDT
The German Federal Supreme Court has granted the appeal by Eli Lilly and Company (NYSE: LLY) in the case of Eli Lilly and Company v. Actavis, vacating the prior decision denying infringement. The German Supreme Court returned the case to the Court of Appeal (Dusseldorf) for further proceedings. The case concerns whether Lilly's vitamin regimen patent for Alimta® (pemetrexed disodium) would be infringed by a generic competitor that had stated an intention to market a dipotassium salt form of pemetrexed in Germany.
LLY: 79.67 (+0.53)
Testosterone Replacement Therapy (TRT) Market to Face Lean Patch until 2024 as it Inches Close to Patent Cliff, Says TMR
PR Newswire Europe - Tue Jul 12, 11:31AM CDT
ALBANY, New York, July 12, 2016 /PRNewswire/ --
AGN: 239.70 (+1.42), ENDP: 17.39 (+0.23), LLY: 79.67 (+0.53), ABBV: 65.50 (+1.15)
2016 INVESTIndiana Equity Conference Announces Corporate Presentation Lineup
BusinessWire - Tue Jul 12, 10:00AM CDT
INVESTIndiana, an equity conference that highlights the performance of Indiana public companies, today announced a presentation lineup that features Indiana's top health sciences companies as well as leaders in the banking, energy, high-tech and manufacturing sectors.
ESCA: 10.06 (+0.24), ININ: 43.64 (+0.92), ZBH: 125.46 (+0.38), GABC: 34.02 (+0.96), KBAL: 11.72 (+0.01), HBNC: 26.34 (+0.27), LLY: 79.67 (+0.53), LKFN: 48.01 (+0.96), SRCE: 33.11 (+0.40), ONB: 12.94 (+0.28), ECYT: 3.24 (+0.05), NI: 25.86 (-0.21), INBK: 24.63 (+0.25), BASI: 1.20 (-0.03), MFSF: 28.64 (+0.28)
Technical Report on Drug Manufacturers - Major Stocks - Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and GlaxoSmithKline
PR Newswire - Mon Jul 11, 6:55AM CDT
On Friday, July 08, 2016, the NASDAQ Composite ended the trading session at 4,956.76, up 1.64%; the Dow Jones Industrial Average advanced 1.40%, to finish at 18,146.74; and the S&P 500 closed at 2,129.90, up 1.53%. The gains were broad based as all the sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Bristol-Myers Squibb Company (NYSE: BMY), AstraZeneca PLC (NYSE: AZN), Eli Lilly and Company (NYSE: LLY), and GlaxoSmithKline PLC (NYSE: GSK). Learn more about these stocks by accessing their free notes at:
AZN: 30.20 (+0.23), LLY: 79.67 (+0.53), GSK: 43.72 (+0.20), BMY: 76.20 (+0.81)
Lilly Diabetes Welcomes Acclaimed Singer/Songwriter Crystal Bowersox as Newest Spokesperson
PR Newswire - Wed Jul 06, 5:45AM CDT
Crystal Bowersox understands how crucial it is to properly manage diabetes and find a healthy balance on and off the stage. Diagnosed with type 1 diabetes at age 6, Crystal - now 30 - rose from humble beginnings in northwestern Ohio to reach the heights of American Idol in 2010 and an ongoing musical career that has followed. Having nearly lost her spot on the show due to a short hospitalization brought on by the rigorous taping and rehearsal schedule, she vowed to make it her mission to touch others impacted by diabetes with her music and her message.
LLY: 79.67 (+0.53)
Top 6 Research Reports for July 1, 2016
Sheraz Mian - Zacks Investment Research - Fri Jul 01, 12:59PM CDT
Top 6 Research Reports for July 1, 2016
FDX: 159.95 (+2.84), HII: 173.14 (-0.72), CCL: 46.71 (+1.08), LLY: 79.67 (+0.53), ORCL: 41.42 (+0.64), WEN: 9.78 (unch)
Merus Labs Appoints Two New Senior Executives
PR Newswire - Thu Jun 30, 3:00PM CDT
Merus Labs International Inc. ("Merus" or the "Company"
(TSX: MSL, NASDAQ: MSLI) is pleased to announce two key additions to its executive leadership team effective July 1, 2016. LLY: 79.67 (+0.53), MSLI: 1.28 (+0.03)
Eli Lilly Stock Up on FDA Advisory Panel Vote for Jardiance
Arpita Dutt - Zacks Investment Research - Thu Jun 30, 8:50AM CDT
Lilly (LLY) and its partner, Boehringer, are seeking FDA approval for the inclusion of data from the EMPA-REG OUTCOME study, which showed cardiovascular risk reduction.
JNJ: 122.92 (-0.01), NVO: 55.55 (+0.19), MRK: 59.60 (+0.26), LLY: 79.67 (+0.53)
SmarTrend Watching for Potential Pullback in Shares of Eli Lilly After 3.89% Gain
Comtex SmarTrend(R) - Wed Jun 29, 12:45PM CDT
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $75.87 to a high of $78.14. Yesterday, the shares gained 3.9%, which took the trading range above the 3-day high of $76.25 on volume of 3.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
LLY: 79.67 (+0.53)
Lilly Confirms Date And Conference Call For Second-Quarter 2016 Financial Results Announcement
PR Newswire - Tue Jun 28, 12:37PM CDT
Eli Lilly and Company (NYSE: LLY) will announce its financial results for the second quarter of 2016 on Tuesday, July 26, 2016. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance.
LLY: 79.67 (+0.53)
Lilly Convenes Leaders at National Mayor's Conference to Address Impact of Alzheimer's Disease on Local Communities
PR Newswire - Mon Jun 27, 1:30PM CDT
With the prevalence of Alzheimer's disease expected to triple by 2050, there is an urgent need for greater awareness of the economic and social impact of the disease on families, communities and health systems. In an effort to educate and activate local communities to plan for this emerging public health crisis, Eli Lilly and Company (NYSE:LLY) today kicked off an expansion of its Community Conversations on Alzheimer's series with a panel discussion at the U.S. Conference of Mayors meeting in Indianapolis, Indiana.
LLY: 79.67 (+0.53)
Elanco Animal Health Announces One Health Antibiotic Stewardship Summit
PR Newswire - Mon Jun 27, 10:40AM CDT
Last June leaders from across human and animal health gathered at the White House Forum on Antibiotic Stewardship to improve antibiotic stewardship and to protect long-term effectiveness of antibiotics. Building on the collaboration created at that event, Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY), is announcing a One Health Antibiotic Stewardship Summit for global industry and food chain leaders to continue building dialogue and actions that address this challenge.
LLY: 79.67 (+0.53)
Incyte Gains on Jakafi's Breakthrough Status for Acute GVHD
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 5:07PM CDT
Incyte (INCY) announced that the FDA has granted Breakthrough Therapy status to Jakafi for the treatment of patients with acute graft-versus-host disease.
INCY: 84.97 (-0.03), LLY: 79.67 (+0.53), BMY: 76.20 (+0.81), NVS: 81.68 (-0.63)
Diabetes Scholars Foundation Announces 2016 Scholarship Recipients
PR Newswire - Thu Jun 23, 9:00AM CDT
If the caliber of students receiving a Lilly Diabetes Tomorrow's Leaders Scholarship is any indication, the future is in good hands. The 2016 scholarship winners, announced today online at www.diabetesscholars.org by the Diabetes Scholars Foundation (Foundation), refused to let type 1 diabetes stand in the way of academic and community service excellence.
LLY: 79.67 (+0.53)
MacroStat Receives 2016 Lilly Global Supplier Award
BusinessWire - Wed Jun 22, 10:51AM CDT
MacroStat, a leading biometrics CRO fully owned by Tigermed (ChiNext SZ: 300347), has received the 2016 Lilly Global Supplier Award that recognizes MacroStat's outstanding performance in the area of biometrics services for Eli Lilly and Company (NYSE: LLY).
LLY: 79.67 (+0.53)
Cancer Drug News Issue - Global Expansion of Portrazza will Aid in Supporting Eli Lilly's Lung Cancer Franchise - Research and Markets
BusinessWire - Tue Jun 21, 12:32PM CDT
Research and Markets has announced the addition of the "Cancer Drug News Issue 670" report to their offering.
LLY: 79.67 (+0.53)
Lilly Declares Third-Quarter 2016 Dividend
PR Newswire - Mon Jun 20, 12:00PM CDT
The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2016 of $0.51 per share on outstanding common stock.
LLY: 79.67 (+0.53)
Elanco, EnBiotix Establish Collaboration Exploring Engineered Phage Technology
BusinessWire - Thu Jun 16, 7:00AM CDT
Today Elanco Animal Health, a division of Eli Lilly and Company, (NYSE: LLY) and EnBiotix, Inc., announced a collaboration to explore the application of EnBiotix's engineered phage technology in specific animal health targets. If successful, this endeavor could result in potential alternatives for traditional antibiotics in animals.
LLY: 79.67 (+0.53)
German Supreme Court Grants Lilly Appeal in Alimta® Vitamin Regimen Patent Lawsuit
PR Newswire - Tue Jun 14, 5:15PM CDT
The German Federal Supreme Court has granted the appeal by Eli Lilly and Company (NYSE: LLY) in the case of Eli Lilly and Company v. Actavis, vacating the prior decision denying infringement. The German Supreme Court returned the case to the Court of Appeal (Dusseldorf) for further proceedings. The case concerns whether Lilly's vitamin regimen patent for Alimta® (pemetrexed disodium) would be infringed by a generic competitor that had stated an intention to market a dipotassium salt form of pemetrexed in Germany.
LLY: 79.67 (+0.53)
